The primary purpose of this study is to evaluate the efficacy of DAPA for the treatment of coronary microvascular dysfunction (CMD) among patients with angina and no obstructive coronary artery disease (ANOCA) and established CMD as compared to placebo.
Participant is older than 18 years of age
Participant is willing and able to sign informed consent
Participant is willing to comply with the specified follow-up evaluations
Anginal Symptoms (chest pain, pressure, dyspnea on exertion, or anginal equivalents
Clinical Diagnosis Type 1 or 2 diabetes on medical treatment
Clinical Diagnosis of Heart failure with preserved ejection fraction (HFpEF)
Symptomatic Postural Orthostatic Tachycardia Syndrome (POTS)
History of coronary artery bypass graft (CABG)